ARP Rheumatology

Home
ARP Rheumatology

The official journal of the Portuguese Society of Rheumatology (). Indexed to PubMed. Both basic research and clinical papers may be submitted.

ARP Rheumatology succeeds Acta Reumatológica Portuguesa, originally founded in 1973 as the official journal of the Portuguese Society of Rheumatology. It is a scientific double-blinded peer-reviewed and open-access journal devoted to progress in the research, diagnosis and treatment of rheumatic and musculoskeletal diseases. The journal aims at serving the interest of both practising clinicians an

d research workers. Editorials, short communications and review articles covering recent developments are included. Controversial techniques and issues on health policy are frequently discussed and serve as tools for encouraging debate. It also concerns about guidelines and clinical protocols related to the practice of rheumatology. The submission has no fees and all articles are available for free.

24/07/2025

📋 Systemic Sclerosis Impact: Now Validated in Portuguese!
How reliable is the EULAR ScleroID for Portuguese patients with SSc?
A validation study with 53 patients shows the Portuguese ScleroID is a feasible, reliable, and valid tool to measure disease impact — with strong psychometric properties and clinical relevance.

🧪 High internal consistency
📊 Valid construct structure
✅ No floor/ceiling effects

🔗 Read more: https://www.arprheumatology.com/article_abstract.php?id=1587

09/07/2025

We are pleased to welcome Dr. Cristiana Seiro Santos as our new Website and Social Media Editor. Starting in July 2025, she will collaborate closely with Ricardo Ferreira, who continues in his role as Website Editor. We thank the dedication of Dr. Daniela Faria, who served ARP Rheumatology on this role for the last 4 years with great commitment. We AIM to continue enhancing ARP Rheumatology’s digital presence.
We are also happy to confirm that João Cavaleiro will remain as Technical Editor of the ARP Rheumatology Journal — a position he has held with distinction since 2006. His expertise continues to ensure the flow of the work and liason with external databases and partners.
We are looking forward to receive your manuscripts and to provide you with the latest scientific discoveries in the field of .

05/07/2025

We are proud to announce Prof. Tânia Santiago as the new Editor-in-Chief!
A leading rheumatologist at Centro Hospitalar e Universitário de Coimbra with a PhD on systemic sclerosis and ultrasound imaging, Prof. Santiago brings deep clinical insight and academic excellence to the role. With around 100 scientific publications, her contributions to rheumatology and autoimmune research are widely recognized.

Her appointment marks a new chapter in our journal’s pursuit of scientific quality, editorial innovation, and international relevance. We are excited for the direction she will lead us in!
Please join us in warmly welcoming Prof. Tânia Santiago as our new Editor-in-Chief.

04/07/2025

The 2024 Impact Factor (IF) for ARP Rheumatology was just released and is set to 1.4. This is the first IF with the journal new name, a transition that started back in 2022. In that year the Journal's IF was 1.375, which means the new title continues the growing trajectory of the old title, securing its stable position in the third quartile of all rheumatology journals. A further increase in IF in the coming years is not an unrealistic expectation.
Thank you to our authors, reviewers, Associate Editors and community for making this possible!

03/07/2025

👏 A heartfelt thank you to Professor Alexandre Sepriano for his outstanding service and unparalleled commitment as Editor-in-Chief of ARP Rheumatology! 👏

During his tenure, Alexandre not only led the team with excellence but also drove significant improvements to the journal, fostering its international reach. He oversaw the name change, transitioned the journal fully to English, and transformed the submission process — all of which have enhanced the quality and efficiency of our editorial work. His vision and dedication have made a lasting impact, and the future is very promising.

We are truly grateful for his invaluable contributions and inspiring leadership!

02/07/2025

📢 Now available: ARP Rheumatology Vol. 4, No. 2 (2025)
This issue presents a diverse selection of original research, reviews, and case reports, including:
🔹 The role of AI in medical research and its implications for critical thinking
🔹 Interleukin-based biomarkers in lupus nephritis
🔹 Cross-national analysis of methotrexate patient education (26 European countries)
🔹 COVID-19’s impact on connective tissue disease-associated ILD
🔹 Rare presentations of vasculitis and therapeutic challenges in PMR
🔹 Culturally adapted assessment tools for systemic sclerosis and juvenile fibromyalgia
📖 Explore the latest developments in rheumatology from an international, evidence-based perspective.
🔗 https://www.arprheumatology.com/archive_detail.php?id=256

09/06/2025

💊 Methotrexate Education Across Europe: Are Patients Getting Enough Support?
How well are patients with rheumatic diseases being educated about MTX?

A large survey across 26 European countries (n=2316) explored the experiences of patients, carers, nurses, and physicians regarding methotrexate (MTX) education and support in rheumatology care.

🔗 Read more:
https://www.arprheumatology.com/article_abstract.php?id=1594

07/05/2025

🫁 COVID-19 Outcomes in ILD: CTD-ILD vs. IIP
How does pre-existing lung disease affect COVID-19 risk? This nationwide study analyzed over 1 million hospitalizations and found both CTD-ILD and IIP patients faced significantly higher mortality than those without ILD. ⚠️

🔍 Understanding ILD subtype impact is critical for risk stratification and future research on targeted care for ILD patients during infectious disease outbreaks.

Read more: https://www.arprheumatology.com/article_abstract.php?id=1583

02/05/2025

🧪 Gaps in Still’s Disease Management Highlighted in New Survey.

Still’s Disease (sJIA & AOSD) remains challenging to manage. A cross-sectional study in Portugal found limited implementation of 2024 EULAR/PreS recommendations. These findings underscore the need for broader awareness and adoption of biomarker-based diagnostics and early biologic intervention to improve outcomes. 🧠📈

📖 Read more: https://www.arprheumatology.com/article_abstract.php?id=1582

21/04/2025

🧪 Biomarkers Predict Kidney Damage in Lupus (SLE)

SLE often affects the kidneys, leading to lupus nephritis (LN). This study found IL-17, IL-23 & IL-10 levels were significantly elevated in SLE—especially in severe LN (class III/IV). 📈

These biomarkers show strong potential for predicting LN class and activity, offering a non-invasive tool for better disease monitoring. 🔍💡

🔎 Clinical assessment + biomarker profiling could improve outcomes in SLE nephritis!

Read more: https://www.arprheumatology.com/article_abstract.php?id=1580

05/04/2025

📢 Now Available: ARP Rheumatology Vol 4, No 1 (2025)
Start the year with the latest insights in rheumatology! The new issue of ARP Rheumatology is packed with original research, reviews, and case-based reviews, images and letters exploring emerging

👉 Explore the full issue fully available here:
🔗 https://www.arprheumatology.com/archive_detail.php?id=255

28/11/2024

➡Better Care for Axial SpA Patients!
Did you know education can be as powerful as exercise in managing axial spondyloarthritis (axSpA)?

🌐Read more: https://www.arprheumatology.com/article_abstract.php?id=1555

Address

Website

http://www.arprheumatology.com/

Alerts

Be the first to know and let us send you an email when ARP Rheumatology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to ARP Rheumatology:

Shortcuts

Address
Alerts
Contact The Business
Want your business to be the top-listed Media Company?

Country:

City: